ASX ANNOUNCEMENT Registration details for Actinogen’s August 12 Clinical Trials Science Forum webinar on the future of Alzheimer's treatment Sydney, 5 August 2026. Actinogen Medical ASX: ACW (“ACW” or “the Company”) will host a live Clinical Trials Science Forum webinar at 11am...
ACW webinar on the future of Alzheimers treatment
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The event will feature discussions led by the CEO and Chief Commercial Officer, along with expert neurologists. This webinar aims to provide insights into evolving diagnostic and treatment approaches for Alzheimer's disease. Registration details for the event are included in the announcement, which also mentions that a recording will be available afterward.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Actinogen Medical Limited on 6ix
In the deck
Story so far
Earlier from Actinogen Medical
- June 2026 Quarterly activity report & Appendix 4C
- Application for quotation of securities - ACW
- Xanamem depression trial published in British J Psychiatry
- ACW third positive XanaMIA trial data committee review
- Actinogen receives positive EMA scientific advice aligned with prior FDA guidance for its Alzheimer’s disease program
Later from Actinogen Medical
- ACW Bioshares presentation, strong cortisol rationale
- Notification of cessation of securities - ACW
- Updated Securities Trading Policy
- ACW webinar today, The future of Alzheimers treatment
- Appendix 3Y-Malcolm McComas
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical